Browsing Tag
Moderna
36 posts
What happened to Moderna’s combo COVID–flu–RSV vaccine—and is it still in the race for 2026?
Moderna’s combo COVID–flu vaccine has been delayed to 2026 after FDA feedback. Find out what caused the setback and whether the mRNA-1083 shot can still launch next year.
NB.1.8.1 variant triggers global COVID-19 surge amid endemic transition
NB.1.8.1 variant drives global COVID-19 surge; China, Australia report highest transmission. WHO classifies risk as low but urges continued vaccine surveillance.
JN.1 variant: Why it still dominates global COVID-19 cases in mid-2025
JN.1 remains the most dominant COVID-19 variant in mid-2025. Explore why it still leads global cases, what WHO and CDC recommend, and how vaccines are adapting.
Fall 2025 COVID booster update: FDA endorses JN.1-based vaccine as dominant LP.8.1 strain spreads
FDA backs fall 2025 COVID booster targeting LP.8.1; rollout to begin by August. New vaccine expected to offer stronger protection against dominant variants.
Sarepta, Palantir, Moderna lead Wall Street declines as biotech, tech stocks tumble
U.S. stock market losers on May 6, 2025: Find out why Sarepta, Palantir, Moderna, Lattice Semiconductor and more saw sharp stock price drops.
US stock market declines as Vaxcyte, Biohaven, and Moderna lead losses
US stocks closed sharply lower on March 31, 2025, led by biotech and tech losses. Learn why markets are reacting to tariffs, interest rates, and economic uncertainty.
China discovers new bat coronavirus HKU5-CoV-2: How serious is the threat?
A newly identified bat coronavirus, HKU5-CoV-2, has been discovered by Chinese scientists, raising concerns about animal-to-human transmission and…
HHS invests $590m in Moderna for mRNA-based pandemic influenza vaccines
The U.S. Department of Health and Human Services (HHS) has announced a monumental $590 million investment in Moderna,…
First U.S. bird flu death sparks health concerns: What you should know
The United States has reported its first human fatality from the H5N1 avian influenza, a development raising critical…
Merck invests $50m in Personalis to bolster Moderna collaboration on individualized cancer therapies
Personalis, Inc., a leader in precision oncology solutions, has secured a significant investment from Merck and extended its…